Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Flatt

Showing results (41-50 of 325) with videos related to

Pageof 33
Sort By:
Expert Opinion on Investigational Drugs|July 16, 2010
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazoneClifford J Bailey, Brian D Green, Peter R Flatt
Biochemical Pharmacology|April 27, 2010
Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1Barry D Kerr, Peter R Flatt, Victor A Gault
The Journal of Endocrinology|September 28, 2006
Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinideNeville H McClenaghan, Peter R Flatt, Andrew J Ball
Peptides|January 7, 2023
An update on peptide-based therapies for type 2 diabetes and obesityClifford J Bailey, Peter R Flatt, J Michael Conlon
European Journal of Pharmacology|January 15, 2008
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) miceNigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Peptides|December 12, 2022
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetesWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Biochemical Pharmacology|August 26, 2010
(D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actionsBarry D Kerr, Peter R Flatt, Victor A Gault
British Journal of Pharmacology|May 25, 2004
Acute and long-term effects of nateglinide on insulin secretory pathwaysAndrew J Ball, Peter R Flatt, Neville H McClenaghan
Frontiers in Bioscience : a Journal and Virtual Library|May 30, 2008
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetesPeter R Flatt, Clifford J Bailey, Brian D Green
Regulatory Peptides|December 17, 2008
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed miceNigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Pageof 33

Showing results (41-50 of 325) with videos related to

Sort By:
Pageof 33
Expert Opinion on Investigational Drugs|July 16, 2010
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazoneClifford J Bailey, Brian D Green, Peter R Flatt
Biochemical Pharmacology|April 27, 2010
Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1Barry D Kerr, Peter R Flatt, Victor A Gault
The Journal of Endocrinology|September 28, 2006
Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinideNeville H McClenaghan, Peter R Flatt, Andrew J Ball
Peptides|January 7, 2023
An update on peptide-based therapies for type 2 diabetes and obesityClifford J Bailey, Peter R Flatt, J Michael Conlon
European Journal of Pharmacology|January 15, 2008
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) miceNigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Peptides|December 12, 2022
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetesWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Biochemical Pharmacology|August 26, 2010
(D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actionsBarry D Kerr, Peter R Flatt, Victor A Gault
British Journal of Pharmacology|May 25, 2004
Acute and long-term effects of nateglinide on insulin secretory pathwaysAndrew J Ball, Peter R Flatt, Neville H McClenaghan
Frontiers in Bioscience : a Journal and Virtual Library|May 30, 2008
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetesPeter R Flatt, Clifford J Bailey, Brian D Green
Regulatory Peptides|December 17, 2008
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed miceNigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Pageof 33